Opioid Use Disorder
Conditions
Brief summary
This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the \[11C\]-UCB-J radiotracer while inpatient.
Detailed description
Participants will undergo screening as outpatients at the Clinical Neuroscience Research Unit (CNRU). Once deemed eligible, OUD subjects will be studied as inpatients. However, they will have the option of scheduling their second \[11C\]-UCB-J PET as an outpatient (pending these participants' agreement to undergo outpatient visits twice per week to provide urine toxicology to monitor abstinence before PET). The only portion of the study that will be available as outpatient for OUD subjects will be the 1-2 weeks before the second \[11C\]-UCB-J PET scan. The subject will still be admitted for 1-2 weeks, which will include: inpatient detoxification, baseline \[11C\]-UCB-J PET scan, psilocybin administration, and overnight observation after psilocybin administration. However, they may be discharged the day following psilocybin administration and return 2x weekly for urine toxicology testing between discharge and the second \[11C\]-UCB-J PET to confirm abstinence. Structural magnetic resonance imaging (MRI) scans will be obtained for anatomical registration/partial volume correction from all subjects. Functional MRI (fMRI) scans will be completed pre- and post-psilocybin administration to evaluate changes in resting state connectivity. All subjects will participate in a battery of behavioral assessments for exploratory correlations with \[11C\]-UCB-J. Inpatient subjects who smoke cigarettes will have the option of using nicotine gum and/or nicotine patch while on the unit in order to prevent or minimize nicotine withdrawal. The \[11C\]-UCB-J PET scans will be done at the Yale PET Center 1-2 weeks before (baseline) and after psilocybin administration. This is a single-center study at Yale, that will have study activities completed at the following areas: * Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center (CMHC) * Yale Positron Emission Tomography (PET) Imaging Center * Yale Magnetic Resonance Research Center (MRRC)
Interventions
DRUGPsilocybin
Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
Sponsors
Yale University
National Institute on Drug Abuse (NIDA)
Yale Biomedical Imaging Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Participants will be medically healthy females and males with OUD.
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Age between 25 and 55 years * BMI between 19 and 35 kg/m2 * Voluntary, written, informed consent * Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations * DSM-5 criteria for Opioid Use Disorder * Documented evidence (by urine toxicology) of opioid use (upon screening) * Inpatient verified \> 1 week of abstinence from illicit opioids * For females, a negative serum pregnancy (beta-HCG) test * Participants are required to commit to employing dual contraceptive methods throughout the study and to abstain from sperm or egg donation during the study period and for 28 days following the final drug dose for ova, and for 90 days following the final drug dose for sperm. Dual contraceptive methods encompass the use of a barrier contraceptive, such as condoms, coupled with another effective method capable of preventing pregnancy, such as oral or parenteral contraceptives, intrauterine devices, spermicide, and the like.
Exclusion criteria
* DSM-5 criteria for other substance use disorders (e.g., alcohol, cocaine, sedative hypnotics), except for nicotine (concurrent alcohol or drug use is allowed if it does not meet criteria for a substance use disorder and does not take place during inpatient stay) * A primary DSM-5 Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression, as determined by psychiatric history (Mini International Neuropsychiatric Interview, MINI) (Sheehan et al., 1998), or another disorder that may interfere with the study's primary outcomes in the view of PI * Immediate (first-degree relative) family history of formally diagnosed schizophrenia or other psychotic disorders (e.g., delusional disorder, schizoaffective disorder), or bipolar I/II disorder * Individuals with a history or evidence of psychosis, including substance and nonsubstance related, as evaluated in assessments (MINI and Brief Psychiatric Rating Scale \[BPRS\]) before psilocybin administration * History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder * A history of significant and/or uncontrolled medical or neurological illness * Hypertension at screening defined as: systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg * Heart rate outside the range of 60 to 100 beats per minute * History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia * Any clinically significant abnormal electrocardiogram (ECG) finding, such as findings suggestive of ischemia or infarct, complete bundle branch block, atrial fibrillation or other symptomatic arrhythmia, or predominantly non-sinus rhythm, at screening * Resting QT interval with Fridericia's correction (QTcF) ≥ 450 msec at Screening, or inability to determine QTcF interval * Presence of risk factors for torsades de pointes, including: long QT syndrome, uncontrolled hypokalemia or hypomagnesemia, history of cardiac failure, history of clinically significant/symptomatic bradycardia, family history of idiopathic sudden death or congenital long QT syndrome, or concomitant use of a torsadogenic medication * Current use of psychotropic and/or potentially psychoactive prescription medications considered to the investigators are likely to interfere clinically with human subject's safety (i.e., contraindicated drug-drug interactions with psilocybin) or scientifically (i.e., likely to influence or alter outcomes of the study) * Current use of medications with serotonergic activity, as participants on these medications are at risk of serotonin syndrome or drug-drug interactions * Medical contraindications to MRI procedures (e.g., ferromagnetic implants/foreign bodies, claustrophobia, etc.) * Arterial Line Exclusion: Blood donation within eight weeks of the start of the study * Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) * Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale PET Center (21CFR361.1) * Moderate to severe hepatic impairment (Child-Pugh B and C class) * Use of enzyme inhibitors (UGT1A9, UGT1A10, MAO, and aldehyde or alcohol dehydrogenase).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Synaptic Density | baseline and 1-2 weeks post treatment | Change in synaptic density pre- and post- psilocybin administration will be measured using \[11C\]-UCB-J PET (volume of distribution \[VT\] and binding potential \[BPND\]) among OUD. The regions of interest (ROI) will be subregions of the prefrontal cortex identified by preclinical and preliminary clinical studies. |
| Association between VT and BPND | up to 12 weeks | Association between VT and BPND assessed to determine whether changes in VT are associated with changes in BPND. |
| Time to relapse | up to 12 weeks | Mean number of days to relapse assessed by self- report |
| Urine toxicology post treatment | up to 12 weeks | The mean number of positive urine tests post treatment will be assessed. Urine samples will be tested for the presence of opioids. A positive test indicates opioid usage in the last 2 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in vital signs- heart rate (HR) | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in heart rate measured in beats per minute during Psilocybin session |
| Change in vital signs- respiratory rate (RR) | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in respiratory rate measured in breaths per minute during Psilocybin session |
| Change in vital signs- oxygen saturation | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in percent oxygen saturation assessed using a pulse oximeter during Psilocybin session |
| Change in vital signs- systolic blood pressure | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in systolic blood pressure in mmHg during Psilocybin session |
| Change in vital signs- diastolic blood pressure | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in diastolic blood pressure in mmHg during Psilocybin session |
| Change in vital signs- body temperature | immediately prior to psilocybin treatment with and up to 5 hours+ post treatment | Mean change in body temperature in degrees Fahrenheit during Psilocybin session |
| Total number of participants with treatment emergent adverse events | up to 12 weeks | Total number of participants with any treatment emergent adverse events while on study assessed using the Systematic Assessment for Treatment Emergent Events (SAFTEE). |
| Change in Profile of Mood States (POMS) Score | approximately 30 and 150 minutes post Psilocybin treatment | POMS is a validated 30 item questionnaire used to assess an individual's mood states. Total scores range from 0 to 120 with lower scores indicating a better mood state. |
| Change in Clinical Opioid Withdrawal Scale (COWS) Score | approximately 30 and 150 minutes post Psilocybin treatment | COWS is an 11-item scale to rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score determines the stage/severity of opiate withdrawal and assess the level of physical dependence on opioids. Score: 5- 12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal |
| Change in Subjective Opioid Withdrawal Scale (SOWS) Score | approximately 30 and 150 minutes post Psilocybin treatment | SOWS is a self-administered scale for opioid withdrawal symptoms. It has16 symptoms whose intensity is rated on a scale of 0 (not at all) to 4 (extremely). Mild Withdrawal = score of 1-10, Moderate withdrawal = 11-20, Severe withdrawal = 21-30 |
| Change in Opioid Symptom Checklist (OSC) | approximately 30 and 150 minutes post Psilocybin treatment | The OSC is a 13-item opioid symptom checklist consisting of true/false questions designed to measure opioid effects (e.g., "My skin is itchy"). True scores are totaled up to acute opiate positive and negative symptoms and low true scores will mean not feeling any of the negative and positive symptoms. |
Countries
United States
Contacts
CONTACTGustavo Angarita, MD, MHS
PRINCIPAL_INVESTIGATORGustavo Angarita, MD, MHS
Yale University
Outcome results
None listed